Patents by Inventor Yeong-Sang Kim

Yeong-Sang Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nuclear receptor modulators and their use for the treatment and prevention of cancer
    Patent number: 10737995
    Abstract: Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: August 11, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jane B. Neckers, Yeong Sang Kim, Sunmin Lee, Vineet Kumar, Sanjay V. Malhotra
  • NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER
    Publication number: 20190047932
    Abstract: Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 14, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Jane B. Neckers, Yeong Sang Kim, Sunmin Lee, Vineet Kumar, Sanjay V. Malhotra
  • Nuclear receptor modulators and their use for the treatment and prevention of cancer
    Patent number: 10071945
    Abstract: Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: September 11, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jane B. Neckers, Yeong Sang Kim, Sunmin Lee, Vineet Kumar, Sanjay V. Malhotra
  • Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same
    Patent number: 9782399
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: October 10, 2017
    Assignees: The United States of America, as represented by The Secretary, Department of Health and Human Services, The Regents of the University of California, The Board of Regents of The University of Texas System
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Kugelman-Tonos, Heather A. Balsiger, Robert Fletterick
  • PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME
    Publication number: 20160151350
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Application
    Filed: December 1, 2015
    Publication date: June 2, 2016
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Kugelman-Tonos, Heather A. Balsiger, Robert Fletterick
  • Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same
    Patent number: 9233973
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: January 12, 2016
    Assignees: The United States of America, as represented by The Secretary, Department of Health and Human Services, The Regents of the University of California, a California Corporation, Board of Regents, The University of Texas System
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Kugelman-Tonos, Heather A. Balsiger, Robert Fletterick
  • PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME
    Publication number: 20150011516
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 8, 2015
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Tonos de Leon, Heather A. Balsiger, Robert Fletterick
  • Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same
    Patent number: 8859207
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: October 14, 2014
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Texas at El Paso
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Tonos de Leon, Heather Balsiger
  • NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER
    Publication number: 20140171503
    Abstract: Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.
    Type: Application
    Filed: June 15, 2012
    Publication date: June 19, 2014
    Applicants: Human Services
    Inventors: Jane B. Neckers, Yeong Sang Kim, Sunmin Lee, Vineet Kumar, Sanjay V. Malhotra
  • PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME
    Publication number: 20120283215
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Application
    Filed: September 14, 2010
    Publication date: November 8, 2012
    Applicants: The Regents of the University of California, a California Corporation, University of Texas at El Paso, Health and Human Services
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Tonos de Leon, Heather Balsiger, Robert Fletterick
  • Platinum(II) complexes of N-substituted amino dicarboxylates and the preparation method thereof
    Patent number: 6867316
    Abstract: Disclosed are a platinum (II) complex of N-substituted amino dicarboxylate showing antitumor activity represented by the following formula (1) and a preparation method thereof: wherein n is 1 or 2; A—A is a diamine selected from the group consisting of trans-(±)-1,2-diaminocyclohexane, ethylenediamine and 2,2-dimethyl-1,3-propanediamine; and R1 is hydrogen and R2 is RCO or RSO2, wherein R is an alkyl selected from the group consisting of methyl, ethyl, n-propyl, n-butyl and t-butyl or an aryl selected from the group consisting of phenyl and substituted phenyl group, or R1R2 is phthaloyl.
    Type: Grant
    Filed: January 8, 2004
    Date of Patent: March 15, 2005
    Assignee: Board of Trustees, Ewha Womans University
    Inventors: Youn Soo Sohn, Yeong-Sang Kim, Rita Song
  • Platinum(II) complexes of N-substituted amino dicarboxylates and the preparation method thereof
    Publication number: 20040162342
    Abstract: Disclosed are a platinum (II) complex of N-substituted amino dicarboxylate showing antitumor activity represented by the following formula (1) and a preparation method thereof: 1
    Type: Application
    Filed: January 8, 2004
    Publication date: August 19, 2004
    Applicant: Board of Trustees, EWHA Womans University
    Inventors: Youn Soo Sohn, Yeong-Sang Kim, Rita Song
  • Orthogonal frequency division multiplexing receiver system
    Patent number: 6470030
    Abstract: An OFDM receiver system for performing precise OFDM demodulation is provided. The OFDM receiver system performs demodulation by sharing memories and operators in a time-divisional manner. FFT-processed data is separated into specific pilot signals and data according to the timing indicated by a controller to then be rearranged and stored, thereby facilitating extraction of corresponding pilot signals and data for various synchronization and equalization steps. Therefore, the demodulation system having an optimal structure can be realized in view of resource utilization efficiency and chip areas, the cost and time for fabricating and designing the system can be reduced, and verification of the system can be easily performed.
    Type: Grant
    Filed: March 3, 1999
    Date of Patent: October 22, 2002
    Assignee: Daewoo Electronics Co., Ltd.
    Inventors: Jae Hyeok Park, Yeong Sang Kim, Jean Jacques Michel, Francois Langinieux, Olivier Dejonghe